HK1138567A1 - Crystalline forms of (3s)-3-[n-(n-(2-tert- butylphenyl)oxamyl)alaniwyl]amino-5-(2,3,5,6-tetrafluoro phenoxy)-4- 0x0penta noic acid (3s)-3-[n-(n-(2-))]-5-(2356- )-4- - Google Patents
Crystalline forms of (3s)-3-[n-(n-(2-tert- butylphenyl)oxamyl)alaniwyl]amino-5-(2,3,5,6-tetrafluoro phenoxy)-4- 0x0penta noic acid (3s)-3-[n-(n-(2-))]-5-(2356- )-4-Info
- Publication number
- HK1138567A1 HK1138567A1 HK10104322.9A HK10104322A HK1138567A1 HK 1138567 A1 HK1138567 A1 HK 1138567A1 HK 10104322 A HK10104322 A HK 10104322A HK 1138567 A1 HK1138567 A1 HK 1138567A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- alaniwyl
- 0x0penta
- oxamyl
- butylphenyl
- tert
- Prior art date
Links
- 239000005950 Oxamyl Substances 0.000 title 1
- 239000002253 acid Substances 0.000 title 1
- KZAUOCCYDRDERY-UHFFFAOYSA-N oxamyl Chemical compound CNC(=O)ON=C(SC)C(=O)N(C)C KZAUOCCYDRDERY-UHFFFAOYSA-N 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
- C07C235/70—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups and doubly-bound oxygen atoms bound to the same carbon skeleton
- C07C235/72—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups and doubly-bound oxygen atoms bound to the same carbon skeleton with the carbon atoms of the carboxamide groups bound to acyclic carbon atoms
- C07C235/74—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups and doubly-bound oxygen atoms bound to the same carbon skeleton with the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of a saturated carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
- C07C237/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton
- C07C237/22—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton having nitrogen atoms of amino groups bound to the carbon skeleton of the acid part, further acylated
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
- C07C235/42—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton
- C07C235/44—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring
- C07C235/52—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring having the nitrogen atom of at least one of the carboxamide groups bound to an acyclic carbon atom of a hydrocarbon radical substituted by carboxyl groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Gastroenterology & Hepatology (AREA)
- Pain & Pain Management (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US86874806P | 2006-12-06 | 2006-12-06 | |
| PCT/IB2007/003900 WO2008068615A1 (en) | 2006-12-06 | 2007-12-03 | Crystalline forms of ( 3 s ) -3- [n- (n' - (2-tert-butylphenyl) oxamyl) alaninyl] amino-5- (2 ', 3 ', 5 ', 6 ' -tetrafluoro phenoxy) -4-0x0penta noic acid |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HK1138567A1 true HK1138567A1 (en) | 2010-08-27 |
Family
ID=39205161
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HK10104322.9A HK1138567A1 (en) | 2006-12-06 | 2010-05-03 | Crystalline forms of (3s)-3-[n-(n-(2-tert- butylphenyl)oxamyl)alaniwyl]amino-5-(2,3,5,6-tetrafluoro phenoxy)-4- 0x0penta noic acid (3s)-3-[n-(n-(2-))]-5-(2356- )-4- |
| HK15100168.9A HK1199885A1 (en) | 2006-12-06 | 2015-01-07 | Crystalline forms of (3s)-3-[n-(n-(2-tert- butylphenyl)oxamyl)alaniwyl]amino-5-(2,3,5,6-tetrafluoro phenoxy)-4-0x0penta noic acid (3s)-3-[n-(n-(2-))]-5-(2356- )-4- |
| HK15100810.1A HK1200440A1 (zh) | 2006-12-06 | 2015-01-23 | 種抑制劑的結晶形式 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HK15100168.9A HK1199885A1 (en) | 2006-12-06 | 2015-01-07 | Crystalline forms of (3s)-3-[n-(n-(2-tert- butylphenyl)oxamyl)alaniwyl]amino-5-(2,3,5,6-tetrafluoro phenoxy)-4-0x0penta noic acid (3s)-3-[n-(n-(2-))]-5-(2356- )-4- |
| HK15100810.1A HK1200440A1 (zh) | 2006-12-06 | 2015-01-23 | 種抑制劑的結晶形式 |
Country Status (23)
| Country | Link |
|---|---|
| US (1) | US7692038B2 (es) |
| EP (1) | EP2091910B1 (es) |
| JP (1) | JP5495787B2 (es) |
| KR (1) | KR101125932B1 (es) |
| CN (3) | CN101573328B (es) |
| AR (1) | AR064809A1 (es) |
| AU (1) | AU2007330478B2 (es) |
| CA (1) | CA2669849C (es) |
| CL (1) | CL2007003491A1 (es) |
| DK (1) | DK2091910T3 (es) |
| ES (1) | ES2524021T3 (es) |
| HK (3) | HK1138567A1 (es) |
| HN (1) | HN2007000536A (es) |
| IL (1) | IL198732A (es) |
| MX (1) | MX2009006055A (es) |
| NO (1) | NO338908B1 (es) |
| PA (1) | PA8759501A1 (es) |
| PE (1) | PE20081251A1 (es) |
| PL (1) | PL2091910T3 (es) |
| PT (1) | PT2091910E (es) |
| TW (1) | TWI345466B (es) |
| UY (1) | UY30758A1 (es) |
| WO (1) | WO2008068615A1 (es) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL3150610T3 (pl) * | 2010-02-12 | 2020-02-28 | Pfizer Inc. | Sole i polimorfy 8-fluoro-2-{4-[(metyloamino}metylo]fenylo}-1,3,4,5-tetrahydro-6Hazepino[5,4,3-cd]indol-6-onu |
| CN103113405B (zh) * | 2012-10-17 | 2016-03-02 | 上海日馨生物科技有限公司 | 苯磷硫胺多晶型体、制备方法及其应用 |
| EA036325B1 (ru) * | 2014-03-14 | 2020-10-27 | Аджиос Фармасьютикалз, Инк. | Фармацевтическая композиция на основе твердой дисперсии ингибитора idh1 |
| MX2016014731A (es) | 2014-05-12 | 2017-05-04 | Conatus Pharmaceuticals Inc | Tratamiento de las complicaciones de la enfermedad cronica del higado con enfermedades de caspasa. |
| WO2016038500A1 (en) * | 2014-09-08 | 2016-03-17 | Pfizer Inc. | Crystalline solid forms of 6-carboxy-2-(3,5-dichlorophenyl)-benzoxazole |
| CA2975048C (en) | 2015-01-30 | 2024-01-02 | Biomed Valley Discoveries, Inc. | Crystalline forms of c21h22ci2n4o2 |
| US20180044375A1 (en) | 2015-03-06 | 2018-02-15 | Concert Pharmaceuticals, Inc. | Deuterated emricasan |
| CN105017061B (zh) * | 2015-07-07 | 2017-03-29 | 苏州富士莱医药股份有限公司 | 一种恩利卡生的合成方法 |
| WO2017079566A1 (en) | 2015-11-05 | 2017-05-11 | Conatus Pharmaceuticals, Inc. | Caspase inhibitors for use in the treatment of liver cancer |
| EP3397251A1 (en) | 2015-12-31 | 2018-11-07 | Conatus Pharmaceuticals, Inc. | Methods of using caspase inhibitors in treatment of liver disease |
| JP2019530696A (ja) | 2016-10-05 | 2019-10-24 | ノバルティス アーゲー | 線維性、硬変性の疾患もしくは障害を治療または予防するためのｆｘｒアゴニストを含む組合せ組成物 |
| JP7113831B2 (ja) * | 2017-01-23 | 2022-08-05 | チア タイ ティエンチン ファーマシューティカル グループ カンパニー リミテッド | カスパーゼ阻害薬としての二環式化合物 |
| WO2018172950A1 (en) * | 2017-03-23 | 2018-09-27 | Novartis Ag | Anhydrous crystalline forms of sodium (s)-2-(diphenylacetyl)-1,2,3,4-tetrahydro-6-methoxy-5-(phenylmethoxy)-3-isoquinolinecarboxylate |
| CA3058280C (en) * | 2017-03-30 | 2023-11-28 | Merck Patent Gmbh | Crystalline form of (s)-[2-chloro-4-fluoro-5-(7-morpholin-4-ylquinazolin-4-yl)phenyl]-(6-methoxy-pyridazin-3-yl)-methanol |
| AR114251A1 (es) * | 2018-02-13 | 2020-08-12 | Syngenta Participations Ag | Formas cristalinas de n-[2-(2,4-diclorofenil)ciclobutil]-2-(trifluorometl)piridin-3-carboxamida |
| CA3105352A1 (en) | 2018-06-29 | 2020-01-02 | Histogen, Inc. | (s)-3-(2-(4-(benzyl)-3-oxopiperazin-1-yl)acetamido)-4-oxo-5-(2,3,5,6-tetrafluorophenoxy)pentanoic acid derivatives and related compounds as caspase inhibitors for treating cardiovascular diseases |
| MX2021010603A (es) | 2019-03-07 | 2022-01-31 | Conatus Pharmaceuticals Inc | Inhibidores de caspasa y metodos de uso de los mismos. |
| CN111351780A (zh) * | 2019-12-29 | 2020-06-30 | 中船重工（邯郸）派瑞特种气体有限公司 | 一种三氟甲基磺酰氟电解槽中电解液成分的分析方法 |
| WO2022123062A1 (en) | 2020-12-11 | 2022-06-16 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Blocking caspase and/or fasl for preventing fatal outcome in covid-19 patients |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE69217762T2 (de) * | 1991-07-30 | 1997-10-09 | Ajinomoto Kk | Kristalle von N-(Trans-4-isopropylcyclohexylcarbonyl)-D-phenylalanin und Verfahren zu ihrer Herstellung |
| DE59307210D1 (de) * | 1993-05-12 | 1997-10-02 | Heumann Pharma Gmbh & Co | Stabile und kristalline Form von Bezafibrat |
| US6197750B1 (en) * | 1998-07-02 | 2001-03-06 | Idun Pharmaceuticals, Inc. | C-terminal modified oxamyl dipeptides as inhibitors of the ICE/ced-3 family of cysteine proteases |
| US7053056B2 (en) * | 1998-07-02 | 2006-05-30 | Idun Pharmaceuticals, Inc. | C-terminal modified oxamyl dipeptides as inhibitors of the ICE/ced-3 family of cysteine proteases |
| US6544951B2 (en) * | 1998-07-02 | 2003-04-08 | Idun Pharmaceuticals, Inc. | C-terminal modified oxamyl dipeptides as inhibitors of the ICE/ced-3 family of cysteine proteases |
| GB9923933D0 (en) * | 1999-10-08 | 1999-12-08 | Smithkline Beecham Lab | Novel pharmaceutical |
| CA2469882C (en) * | 2001-12-11 | 2009-09-29 | Kazuo Orita | Novel stable crystals of substituted phenylpropionic acid derivative and process for producing the same |
| CN101217980A (zh) * | 2005-07-11 | 2008-07-09 | 辉瑞有限公司 | 治疗肝纤维化的抗madcam抗体和抗纤维化半胱天冬蛋白酶抑制剂的新组合 |
-
2007
- 2007-12-03 JP JP2009539823A patent/JP5495787B2/ja active Active
- 2007-12-03 CN CN200780045311.8A patent/CN101573328B/zh active Active
- 2007-12-03 CN CN201410057544.1A patent/CN103923169B/zh not_active Expired - Fee Related
- 2007-12-03 KR KR1020097011692A patent/KR101125932B1/ko active IP Right Grant
- 2007-12-03 CN CN201410058519.5A patent/CN103951583B/zh active Active
- 2007-12-03 AU AU2007330478A patent/AU2007330478B2/en not_active Ceased
- 2007-12-03 CA CA2669849A patent/CA2669849C/en active Active
- 2007-12-03 EP EP07859033.8A patent/EP2091910B1/en active Active
- 2007-12-03 ES ES07859033.8T patent/ES2524021T3/es active Active
- 2007-12-03 PT PT78590338T patent/PT2091910E/pt unknown
- 2007-12-03 PL PL07859033T patent/PL2091910T3/pl unknown
- 2007-12-03 DK DK07859033.8T patent/DK2091910T3/en active
- 2007-12-03 MX MX2009006055A patent/MX2009006055A/es active IP Right Grant
- 2007-12-03 WO PCT/IB2007/003900 patent/WO2008068615A1/en active Application Filing
- 2007-12-04 CL CL200703491A patent/CL2007003491A1/es unknown
- 2007-12-04 HN HN2007000536A patent/HN2007000536A/es unknown
- 2007-12-04 UY UY30758A patent/UY30758A1/es not_active Application Discontinuation
- 2007-12-04 PA PA20078759501A patent/PA8759501A1/es unknown
- 2007-12-05 AR ARP070105447A patent/AR064809A1/es not_active Application Discontinuation
- 2007-12-05 PE PE2007001720A patent/PE20081251A1/es not_active Application Discontinuation
- 2007-12-05 TW TW096146304A patent/TWI345466B/zh active
- 2007-12-06 US US11/951,801 patent/US7692038B2/en active Active
-
2009
- 2009-05-13 IL IL198732A patent/IL198732A/en active IP Right Grant
- 2009-05-14 NO NO20091892A patent/NO338908B1/no not_active IP Right Cessation
-
2010
- 2010-05-03 HK HK10104322.9A patent/HK1138567A1/xx not_active IP Right Cessation
-
2015
- 2015-01-07 HK HK15100168.9A patent/HK1199885A1/xx unknown
- 2015-01-23 HK HK15100810.1A patent/HK1200440A1/zh not_active IP Right Cessation
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HK1199885A1 (en) | Crystalline forms of (3s)-3-[n-(n-(2-tert- butylphenyl)oxamyl)alaniwyl]amino-5-(2,3,5,6-tetrafluoro phenoxy)-4-0x0penta noic acid (3s)-3-[n-(n-(2-))]-5-(2356- )-4- | |
| BRPI0807756A2 (pt) | Método para produzir um l-aminoácido. | |
| GB0721394D0 (en) | Compositions for trating parkinson's disease | |
| SI2344465T1 (sl) | Kristaliniäśne oblike (r)-5-(3-kloro-4-(2,3-dihidroksi-propoksi)- benz(z)iliden)-2-(z)-propilimino)-3-o-tolil-tiazolidin-4-ona | |
| EP1850870A4 (en) | COMPOSITION FOR ADJUVANT CONTAINING POLY-GAMMA-GLUTAMIC ACID | |
| PL2514739T3 (pl) | Podstawiony kwas beta-fenylo-alfa-hydroksy-propanowy, sposób prowadzenia syntezy oraz jego zastosowanie | |
| IL198971A0 (en) | Process for preparing 1-(2-ethyl-butyl)-cyclohexanecarboxylic acid | |
| IL177762A0 (en) | Bimatoprost crystalline form i | |
| ATE457126T1 (de) | Pflanzenwachstumsregulierende zusammensetzungen | |
| EP2023730A4 (en) | COMPOUNDS DERIVED FROM BETULIN AS ANTIAPPETANTS FOR PLANT PESTS | |
| IL190880A (en) | Crystalline posidic acid, a method of preparation and a pharmaceutical composition comprising it | |
| PL2307376T3 (pl) | Nowe związki fenyloaminoizonikotynoamidowe | |
| MX2010002407A (es) | Cocristales y composiciones farmaceuticas que los comprenden. | |
| ZA201205641B (en) | Solid containing glutamic acid-n,n-diacetic acid (glda) or a derivative therefrom and method for the production thereof | |
| WO2010008735A3 (en) | Solid states of o-desmethylvenlaf axine salts | |
| FR2903283B1 (fr) | Procede de fabrication d'applicateurs de produits cosmetiques | |
| ZA201002090B (en) | 2-((r)-2-methylpyrrolidin-2-yl)-1h-benzimidazole-4-carboxamide crystalline form 1 | |
| MX2013003863A (es) | Metodo para la preparacion de (3s,3s')4,4'-disulfandilbis(acido 3-aminobutano 1-sulfonico). | |
| IL212603A (en) | A thioester containing and at least one esterase inhibitor, a process for increasing the bioavailability of the theaster by this hut, a pharmacy containing this hut, and a hut containing kit | |
| BRPI0814090A2 (pt) | Método para produzir um l-aminoácido. | |
| EP2160376A4 (en) | NEW CRYSTALLINE FORMS OF ATOVAQUON | |
| FR2905374B1 (fr) | Procede de preparation d'hydroquinone de purete elevee. | |
| DK1915441T3 (da) | Fremgangsmåde til at fjerne bisulfit-biprodukter fra enzymsammensætninger | |
| IL185076A0 (en) | Process for the prepartion of enantiomerically pure 1-substituted-3-aminoalcohols | |
| FR2916441B1 (fr) | Procede de racemisation d'alpha-aminoacetals optiquement actifs. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PC | Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee) |
Effective date: 20191201 |